The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties

Bennett, Robert M.; Friend, Ronald; Jones, Kim Dupree; Ward, Rachel L; Han, Bobby Kwanghoon; Ross, Rebecca

doi:10.1186/ar2783

Cited by 593 publications

(596 citation statements)

References 23 publications

Supporting

Mentioning

567

Contrasting

Unclassified

Order By: Relevance

“…The study investigator answered the first 2 questions, identifying the site and selecting the patient diagnosis or diagnoses. All other questions were completed by the subject in the following 5 questionnaires: 1) demographics (age, sex, education level, work status, marital status, and number of years with chronic pain and other chronic pain disorders), 2) The 2011ModCr (9), 3) the Short Form 36 (SF-36) (15), 4) the Symptom Impact Questionnaire (SIQR; the SIQR is identical to the Revised Fibromyalgia Impact Questionnaire [FIQR], with the exception that the 3 domains do not use the word "fibromyalgia," thus allowing completion by patients with non-FM disorders) (16), and 5) a 28 -anatomic location inventory rating pain and tenderness on a severity scale (range 0 -10). For this last questionnaire, the…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Criteria for the Diagnosis of Fibromyalgia: Validation of the Modified 2010 Preliminary American College of Rheumatology Criteria and the Development of Alternative Criteria

Bennett

Friend

Marcus³

et al. 2014

Arthritis Care & Research

Self Cite

108

View full text Add to dashboard Cite

Objective. To validate the 2011 modification of the 2010 American College of Rheumatology (ACR) preliminary criteria for the diagnosis of fibromyalgia (2011ModCr) and develop alternative criteria in a sample of patients with diverse pain disorders that are commonly seen in everyday practice by pain specialists, rheumatologists, and psychologists. Methods. Eight clinicians from geographically varied locations in the US evaluated patients with chronic pain and psychiatric disorders using a standard set of questions that included the 2011ModCr questions, the Symptom Impact Questionnaire (SIQR), a 28-area pain location inventory (PLI), and the Short Form 36. Alternative diagnostic criteria were developed from the same data set using logistic regression and receiver operating curve analysis. Results. Complete data on 321 patients were evaluated; there were 135 patients with fibromyalgia (according to the 1990 ACR criteria) and 186 patients with 16 other common chronic pain problems. Comparing the 2011ModCr with the 1990 ACR criteria provided a sensitivity of 83%, a specificity of 67%, and a correct classification of 74%. Alternative criteria were derived from the 10-item symptom score from the SIQR symptoms and the 28-area PLI. Maximal diagnostic accuracy was obtained with >17 pain sites (range 0 -28) and an SIQR symptom score of >21 (range 0 -50). These alternative criteria had a diagnostic sensitivity of 81%, a specificity of 80%, and a correct classification of 80%. Conclusion. The 2011ModCr had robust operating characteristics. Alternative criteria based on symptom items from the SIQR and pain locations from the PLI had comparable operating characteristics, with somewhat better specificity and ease of use.

show abstract

Section: Methodsmentioning

confidence: 99%

“…All data were analyzed in Statistica, version 10, using item analysis and Cronbach's alpha. An alternative diagnostic criteria algorithm was explored using the 28-area PLI and the 10-item symptom subscore from the SIQR (16). The PLI and SIQR correlated at r ϭ 0.62, with Cronbach's ␣ ϭ 0.95 and 0.89, respectively.…”

Section: Significance and Innovationsmentioning

confidence: 99%

Criteria for the Diagnosis of Fibromyalgia: Validation of the Modified 2010 Preliminary American College of Rheumatology Criteria and the Development of Alternative Criteria

Bennett

Friend

Marcus³

et al. 2014

Arthritis Care & Research

Self Cite

108

View full text Add to dashboard Cite

show abstract

“…For the 3-measure composite responder analysis, the SF-36 PCS was chosen as a measure of physical function, because scores on the physical function subscale of the FIQ did not correlate with changes in pain, global status, or other functional status measures (26). Recently, a revised version of the FIQ has been developed in an attempt to correct some of the problems of the original version, such as outdated wording, omissions, sex bias, and scoring problems (27). The new FIQ contains complete revisions of several domains to reflect the relative importance of function in assessing the overall impact of fibromyalgia on functional ability and the overall impact of fibromyalgia on the perception of reduced function.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: Results of a randomized, double‐blind, placebo‐controlled trial

Arnold

Gendreau

Palmer³

et al. 2010

Arthritis & Rheumatism

128

View full text Add to dashboard Cite

Objective. To assess the efficacy and safety of milnacipran at a dosage of 100 mg/day (50 mg twice daily) for monotherapy treatment of fibromyalgia.Methods. A double-blind, placebo-controlled trial was performed to assess 1,025 patients with fibromyalgia who were randomized to receive milnacipran 100 mg/day (n ‫؍‬ 516) or placebo (n ‫؍‬ 509). Patients underwent 4-6 weeks of flexible dose escalation followed by 12 weeks of stable-dose treatment. Two composite responder definitions were used as primary end points to classify the response to treatment. The 2-measure composite response required achievement of >30% improvement from baseline in the pain score and a rating of "very much improved" or "much improved" on the Patient's Global Impression of Change (PGIC) scale. The 3-measure composite response required satisfaction of these same 2 improvement criteria for pain and global status as well as improvement in physical function on the Short Form 36 (SF-36) physical component summary (PCS) score.Results. After 12 weeks of stable-dose treatment, a significantly greater proportion of milnacipran-treated patients compared with placebo-treated patients showed clinically meaningful improvements, as evidenced by the proportion of patients meeting the 2-measure composite responder criteria (P < 0.001 in the baseline observation carried forward [BOCF] analysis) and 3-measure composite responder criteria (P < 0.001 in the BOCF). Milnacipran-treated patients also demonstrated significantly greater improvements from baseline on multiple secondary outcomes, including 24-hour and weekly recall pain score, PGIC score, SF-36 PCS and mental component summary scores, average pain severity score on the Brief Pain Inventory, Fibromyalgia Impact Questionnaire total score (all P < 0.001 versus placebo), and Multidimensional Fatigue Inventory total score (P ‫؍‬ 0.036 versus placebo). Milnacipran was well tolerated by most patients, with nausea being the most commonly reported adverse event (placebo-adjusted rate of 15.8%).Conclusion. Milnacipran administered at a dosage of 100 mg/day improved pain, global status, fatigue, and physical and mental function in patients with fibromyalgia.

show abstract

“…10 However, to complete the assessment of the patient in this study, we also used the FIQR questionnaire, a tool used to assess the degree of general disability from which deductions can be made regarding the affected individual's quality of life. 11 On the basis of this questionnaire, the score was divided into mild 0-39, moderate 39-59 and severe 59- …”

Section: Fibromyalgia Survey Questionnaire and Fibromyalgia Impact Qumentioning

confidence: 99%

Use of oxygen-ozone therapy in the treatment of fibromyalgia

2017

View full text Add to dashboard Cite

Fibromyalgia (FM) is a pathology that is manifested by a spectrum of heterogeneous symptoms that are difficult to frame, from both a diagnostic and therapeutic point of view. On one hand, the clinical features are highly variable, and on the other, the pathophysiology has yet to be fully clarified. This paper aims to highlight how oxygen ozone -administered using a precise protocol from the Scientific Society of Oxygen Ozone Therapy -is able to act on several levels of the pathophysiology of FM by virtue of its intrinsic biochemical mechanisms, making it a viable option for treating the disease. The following case studya 45 year old woman who came to our attention due to diffuse pain and a feeling of general tiredness -responded positively to a standard treatment with oxygen-ozone therapy delivered via bi-weekly sessions, for a total of 12 sessions from September to October 2016. The treatment was followed by a maintenance therapy of about one session a month. One month after the end of the 12 sessions, the patient reported a significant improvement in pain, mood, and a significant reduction in fatigue, a new feeling of well-being and an improved quality of sleep. In the light of these results, oxygen-ozone therapy emerges as a viable therapeutic option for the treatment of FM patients.

show abstract

The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties

Cited by 593 publications

References 23 publications

Criteria for the Diagnosis of Fibromyalgia: Validation of the Modified 2010 Preliminary American College of Rheumatology Criteria and the Development of Alternative Criteria

Criteria for the Diagnosis of Fibromyalgia: Validation of the Modified 2010 Preliminary American College of Rheumatology Criteria and the Development of Alternative Criteria

Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: Results of a randomized, double‐blind, placebo‐controlled trial

Use of oxygen-ozone therapy in the treatment of fibromyalgia

Contact Info

Product

Resources

About